Shanxi Kangbao Pharmaceutical company   Report issue

For profit Phase 1 Phase 2
Founded: Changzhi China (1995)
Status: No NME R&D (1995)

Organization Overview

First Clinical Trial
1998
NCT01136863
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Shanxi Kangbao Biological Product Co., Ltd.

Active Ingredients

Drugs in Phase 2 Trials (2)

dolutegravir (tivicay) (1 trial)

lipovirtide (1 trial)

Drugs in Phase 1 Trials (2)

enfuvirtide (fuzeon) (2 trials)

lp-98 (1 trial)

Drugs in Other Trials (1)

felodipine (plendil) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

HIV Infections (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 5
  • # of Trial APIs: 5